Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins

Nature Medicine

Volumn 8, Issue 1, 2002, Pages 27-34

  Reynolds, Louise E ^a   Wyder, Lorenza ^a   Lively, Julie C ^b   Taverna, Daniela ^b   Robinson, Stephen D ^a   Huang, Xiaozhu ^c   Sheppard, Dean ^c   Hynes, Richard O ^b   Hodivala Dilke, Kairbaan M ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; ALPHA INTEGRIN ANTAGONIST; ANGIOGENESIS INHIBITOR; BETA3 INTEGRIN; BETA5 INTEGRIN; INTEGRIN; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HYPOXIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; INTEGRIN BETA CHAINS; INTEGRIN BETA3; INTEGRINS; LYMPHOKINES; MICE; MICE, MUTANT STRAINS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECEPTORS, VITRONECTIN; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0036152857     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0102-27     Document Type: Article

References (45)

1. Clinical applications of angiogenic growth factors and their inhibitors
2. Integrins in vascular development
3. Angiogenesis in cancer and other diseases
4. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
5. Failure of blood-island formation and vasculogenesis in FIk-1-deficient mice
6. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
7. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
8. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
9. 1 integrins
10. 1 and protein kinase A
11. 3 for angiogenesis
12. 3 antagonists promote tumor regression by inducing apoptosis angiogenic blood vessels
13. 3 blocks human breast-cancer growth and angiogenesis in human skin
14. 3 prevents maturation of blood vessels during embryonic neovascularization
15. Definition of two angiogenic pathways by distinct αv integrins
16. 5 in ocular neovascular diseases
17. v integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
18. Integrins and cancer
19. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
20. 3 integrin receptor antagonist
21. vβ3
22. Extensive vasculogenesis, angiogensis, and organogenesis precede lethality in mice lacking all αv integrins
23. 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival
24. 5-deficient mice
25. 1, with the central cell-binding domain of fibronectin
26. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity
27. Genetic approaches to human retinal disorders
28. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
29. Trans-dominant inhibition of integrin function
30. 1
31. 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin
32. "Inside out" signal transduction inhibited by isolated integrin cytoplasmic domains
33. Single subunit chimeric integrins as mimics and inhibitors of endogenous integrin functions in receptor localization, cell spreading and migration, and matrix assembly
34. 5-integrin-negative teratocarcinomas and embryoid bodies
35. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
36. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization
37. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
38. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
39. Synergism between vascular endothelial growth factor and placental growth factor contributs to angiogenesis and plasma extravasation in pathological conditions
40. 3 integrin in the activation of vascular endothelial growth factor receptor-2
41. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins
42. 1 subunit react with proteins in vertebrates, invertebrates, and fungi
43. The phagokinectic tracks of 3T3 Cells
44. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor
45. Modulation of microvascular growth and morphogenesis by reconstituted basement-membrane gel in 3-dimensional cultures of rat aorta - A comparative-study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot